A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs CT 1812 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Cognition Therapeutics
  • Most Recent Events

    • 08 Nov 2017 According to a Cognition Therapeutics media release, data from this trial will be presented at the Stifel 2017 Healthcare Conference.
    • 04 Nov 2017 According to a Cognition Therapeutics media release, data were presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD) meeting.
    • 30 Oct 2017 According to a Cognition Therapeutics media release, the biomarker and clinical results from the study will be presented in a Late-Breaking Poster on November 2, 2017 and as a Late-Breaking Oral Communication on November 4, 2017 at the 10th Clinical Trials on Alzheimer's Disease (CTAD) meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top